141 related articles for article (PubMed ID: 18379834)
1. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis.
Perry ME; Stirling A; Hunter JA
Clin Rheumatol; 2008 Jul; 27(7):923-5. PubMed ID: 18379834
[TBL] [Abstract][Full Text] [Related]
2. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Higashi S; Tomoda K; Tsukano M; Shono M
Clin Rheumatol; 2010 Dec; 29(12):1395-401. PubMed ID: 20440529
[TBL] [Abstract][Full Text] [Related]
3. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis.
Smith GR; Tymms KE; Falk M
Intern Med J; 2004; 34(9-10):570-2. PubMed ID: 15482271
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Higashi S; Tomoda K; Tsukano M; Baba S
Clin Exp Rheumatol; 2007; 25(4):518-22. PubMed ID: 17888205
[TBL] [Abstract][Full Text] [Related]
5. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T
Mod Rheumatol; 2008; 18(2):109-18. PubMed ID: 18369528
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Higashi S; Tomoda K; Tsukano M; Shono M
Rheumatology (Oxford); 2012 Nov; 51(11):2064-9. PubMed ID: 22879465
[TBL] [Abstract][Full Text] [Related]
7. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.
Drewe E; Huggins ML; Morgan AG; Cassidy MJ; Powell RJ
Rheumatology (Oxford); 2004 Nov; 43(11):1405-8. PubMed ID: 15316120
[TBL] [Abstract][Full Text] [Related]
8. [Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis].
Bellissimo S; Ferrucci MG; Gallo A; Stisi S
Reumatismo; 2007; 59(3):240-3. PubMed ID: 17898885
[TBL] [Abstract][Full Text] [Related]
9. Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents.
Roque R; Ramiro S; Cordeiro A; Gonçalves P; Da Canas S; Santos MJ
Clin Rheumatol; 2011 Jun; 30(6):869-70. PubMed ID: 21484228
[No Abstract] [Full Text] [Related]
10. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
Gottenberg JE; Merle-Vincent F; Bentaberry F; Allanore Y; Berenbaum F; Fautrel B; Combe B; Durbach A; Sibilia J; Dougados M; Mariette X
Arthritis Rheum; 2003 Jul; 48(7):2019-24. PubMed ID: 12847696
[TBL] [Abstract][Full Text] [Related]
11. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept.
Ishii W; Kishida D; Suzuki A; Shimojima Y; Matsuda M; Hoshii Y; Ikeda S
Rheumatol Int; 2011 Feb; 31(2):247-50. PubMed ID: 19820941
[TBL] [Abstract][Full Text] [Related]
12. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis.
Kuroda T; Wada Y; Kobayashi D; Murakami S; Sakai T; Hirose S; Tanabe N; Saeki T; Nakano M; Narita I
J Rheumatol; 2009 Nov; 36(11):2409-15. PubMed ID: 19797512
[TBL] [Abstract][Full Text] [Related]
13. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.
Kobak S; Oksel F; Kabasakal Y; Doganavsargil E
Clin Rheumatol; 2007 Dec; 26(12):2191-2194. PubMed ID: 17611708
[TBL] [Abstract][Full Text] [Related]
14. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
[TBL] [Abstract][Full Text] [Related]
15. No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy.
Simsek I; Kaya A; Erdem H; Pay S; Yenicesu M; Dinc A
J Nephrol; 2010; 23(1):119-23. PubMed ID: 20091495
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF therapy in renal amyloidosis in refractory rheumatoid arthritis: a new therapeutic perspective.
Nobre CA; Callado MR; Rodrigues CE; de Menezes DB; Vieira WP
Rev Bras Reumatol; 2010; 50(2):205-10. PubMed ID: 21125155
[TBL] [Abstract][Full Text] [Related]
17. The effect of etanercept on a case of amyloidosis secondary to ankylosing spondylitis: results of 2-year follow-up.
Yilmaz H; Kocabas H; Erkin G
Acta Reumatol Port; 2013; 38(4):299-301. PubMed ID: 24435036
[TBL] [Abstract][Full Text] [Related]
18. Natural history and outcome in systemic AA amyloidosis.
Lachmann HJ; Goodman HJ; Gilbertson JA; Gallimore JR; Sabin CA; Gillmore JD; Hawkins PN
N Engl J Med; 2007 Jun; 356(23):2361-71. PubMed ID: 17554117
[TBL] [Abstract][Full Text] [Related]
19. [A review for recent advances in AA amyloid research and therapeutic approach to AA amyloidosis complicating rheumatoid arthritis].
Tamura H; Hasegawa K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):35-42. PubMed ID: 19252376
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
